NEW YORK (GenomeWeb News) – A set of studies stemming from the Collaborative Oncological Gene-environment Study, or COGS, have roughly doubled the number of common genetic variants implicated in prostate, breast, or ovarian cancer.

Members of the large, international consortium genotyped around 250,000 individuals for the COGS project, aimed at understanding the heritability and genetic risk profiles of the three cancers and their related subtypes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.